Racura Oncology Teams with Emory to Tackle Osimertinib Resistance in Lung Cancer

Strategic Collaboration to Address a Critical Challenge

Racura Oncology has announced a new collaboration with Emory University, a leading cancer research institution in Atlanta, to study the efficacy of its experimental drug (E,E)-bisantrene (RC220) in tackling resistance to osimertinib, a frontline therapy for EGFR-mutated non-small cell lung cancer (NSCLC). This partnership leverages Emory’s cutting-edge osimertinib-resistant cancer models and the expertise of Professor Shi-Yong Sun, a globally recognised authority on lung cancer resistance mechanisms.

The Challenge of Osimertinib Resistance

Osimertinib, marketed as Tagrisso by AstraZeneca, has transformed treatment for patients with EGFR-mutated NSCLC, generating over US$7 billion in sales in 2025. However, despite its initial effectiveness, most patients eventually develop resistance, leading to disease progression. Racura’s RC220 aims to delay or prevent this resistance by targeting the molecular pathways that allow cancer cells to evade osimertinib’s effects.

Scientific Rationale and Early Data

Preliminary results from the collaboration have shown significant synergy between RC220 and osimertinib in mouse models resistant to osimertinib, suggesting that the combination could improve patient outcomes. Professor Sun’s team has extensively studied the molecular drivers of resistance, including MYC, hTERT/telomerase, and topoisomerase IIa, key targets of (E,E)-bisantrene. This mechanistic insight strengthens the scientific foundation for Racura’s ongoing HARNESS-1 clinical trial, which is assessing the safety and efficacy of the drug combination in patients.

Implications for Clinical Development and Partnerships

Beyond supporting the clinical program, the collaboration is expected to generate robust preclinical data that will be critical for regulatory filings and discussions with pharmaceutical partners. Independent validation from a respected institution like Emory enhances the credibility of Racura’s approach and may accelerate commercial opportunities. The project is slated to continue for over a year, with results to be published in peer-reviewed journals, although detailed data sharing will be limited until then.

Looking Ahead

Racura’s collaboration with Emory University represents a significant step in addressing a major unmet need in lung cancer treatment. By combining innovative science with clinical development, the company aims to extend the benefits of osimertinib for patients facing resistance. Investors and industry watchers will be keenly awaiting further data from this partnership as it unfolds.